DrugNot recommended line

Infliximab

Anti-TNF monoclonal antibody

Response rate
Paradoxical worsening reported
Onset
—
Route
IV infusion
Line
Not recommended
IgM effect
N/A
Evidence level
red

Evidence summary

Anti-TNF monoclonal antibodies can paradoxically worsen TRAPS. Four patients developed acute flares within 12 hours of infliximab infusion. Unlike etanercept (soluble receptor mimetic), infliximab crosslinks membrane TNF and may activate TNFR1 signalling. Anti-TNF monoclonal antibodies (infliximab, adalimumab) are generally not recommended in TRAPS.

Safety warnings

  • !Paradoxical inflammatory flares reported in TRAPS

Drug identifiers

DrugBankDB00065 ↗
ATC CodeL04AB02